These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19464425)

  • 21. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood pressure-lowering effects of incretin-based diabetes therapies.
    Lovshin JA; Zinman B
    Can J Diabetes; 2014 Oct; 38(5):364-71. PubMed ID: 25284699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.
    Yabe D; Seino Y
    Prog Biophys Mol Biol; 2011 Nov; 107(2):248-56. PubMed ID: 21820006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The antidiabetic action of camel milk in experimental type 2 diabetes mellitus: an overview on the changes in incretin hormones, insulin resistance, and inflammatory cytokines.
    Korish AA
    Horm Metab Res; 2014 Jun; 46(6):404-11. PubMed ID: 24627103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Similar weight-adjusted insulin secretion and insulin sensitivity in short-duration late autoimmune diabetes of adulthood (LADA) and type 2 diabetes: Action LADA 9 [corrected].
    Juhl CB; Bradley U; Holst JJ; Leslie RD; Yderstraede KB; Hunter S;
    Diabet Med; 2014 Aug; 31(8):941-5. PubMed ID: 24628669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection of pancreatic beta-cells: is it feasible?
    Bonora E
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients.
    Muscelli E; Mari A; Casolaro A; Camastra S; Seghieri G; Gastaldelli A; Holst JJ; Ferrannini E
    Diabetes; 2008 May; 57(5):1340-8. PubMed ID: 18162504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not?
    Reaven GM
    Diab Vasc Dis Res; 2009 Apr; 6(2):133-8. PubMed ID: 20368203
    [No Abstract]   [Full Text] [Related]  

  • 31. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
    Scheen AJ; Paquot N
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
    Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus.
    Garber AJ
    J Am Osteopath Assoc; 2011 Jul; 111(7 Suppl 5):S20-30. PubMed ID: 21813733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge.
    Bode B; Amin A
    Hosp Pract (1995); 2009 Dec; 37(1):7-21. PubMed ID: 20720383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New treatments in type 2 diabetes: a focus on the incretin-based therapies.
    Barnett AH
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):343-53. PubMed ID: 18771570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Deacon CF
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond glycemic control: cardiovascular effects of incretin-based therapies.
    Angeli FS; Shannon RP
    Front Horm Res; 2014; 43():144-57. PubMed ID: 24943305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?
    Aulinger BA; Vahl TP; Prigeon RL; D'Alessio DA; Elder DA
    Am J Physiol Endocrinol Metab; 2016 May; 310(9):E774-81. PubMed ID: 26979523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The potential of incretin-based therapies in type 1 diabetes.
    Suen CS; Burn P
    Drug Discov Today; 2012 Jan; 17(1-2):89-95. PubMed ID: 21920456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Appropriate therapy for type 2 diabetes mellitus in view of pancreatic β-cell glucose toxicity: "the earlier, the better".
    Kaneto H; Matsuoka TA; Kimura T; Obata A; Shimoda M; Kamei S; Mune T; Kaku K
    J Diabetes; 2016 Mar; 8(2):183-9. PubMed ID: 26223490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.